A Phase 2 interventional study of Victoza® and Placebo in Type 1 Diabetes, sponsored by University of Oulu. Status unknown at 3 sites in Finland. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2022-01-25.
Sponsored by University of Oulu · Phase 2, Interventional, and Prevention
The main objectives of the trial are to study whether daily treatment with liraglutide improves insulin secretion and glucose metabolism, and whether liraglutide treatment is tolerable and safe in subjects with preclinical type 1 diabetes aged 18-30 years.
10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's planned enrollment of 42 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →University of Oulu is the lead sponsor of 138 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
Drug: Victoza®
Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
Drug: Placebo
Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
FPIR (first phase insulin response)
First phase insulin response during 10-min IVGTT (intravenous glucose tolerance test )
Time frame: From baseline to 26 and 104 weeks
Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia
Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia
Time frame: From baseline to 26 and 104 weeks
Tolerability
Tolerability: frequency of side effects, particularly hypoglycaemia and gastrointestinal symptoms
Time frame: From baseline to 26 and 104 weeks
Serum C-peptide AUC
Serum C-peptide area under the curve (AUC) during 2-hour OGTT (oral glucose tolerance test)
Time frame: From baseline to 26 and 104 weeks
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oulu